

## Nahdi Medical Co. announces its Interim Financial Results for the Period Ending on 2022-09-30 (Nine Months)

Element List	Current Quarter	Similar Quarter for Previous Year	%Change	Previous Quarter	%Change
Sales/Revenue	2,159	2,041.7	5.75	2,239.5	-3.59
Gross Profit (Loss)	911.1	857.8	6.21	926.3	-1.64
Operational Profit (Loss)	278.5	274.3	1.53	305.8	-8.93
Net Profit (Loss) after Zakat and Tax	253.8	247.5	2.54	268.5	-5.47
Total Comprehensive Income	256.2	243.9	5.04	303.1	-15.47

All figures are in (Millions) Saudi Arabia, Riyals

Element List	Current Quarter	Similar Quarter for Previous Year	%Change
Sales/Revenue	6,477.9	6,093	6.32
Gross Profit (Loss)	2,689.1	2,497.5	7.67
Operational Profit (Loss)	848.7	759.7	11.71



Net Profit (Loss) after Zakat and Tax	759.8	669.3	13.52
Total Comprehensive Income	795.8	644.8	23.42
Total Share Holders Equity (after Deducting Minority Equity)	2,099	1,463.6	43.41
Profit (Loss) per Share	5.84	5.15	

All figures are in (Millions) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	Net Profit increased by 2.6% in the current quarter compared to the same quarter of last year, reaching SAR 253.8 Million, with an increase of SAR 6.4 Million compared to SAR 247.5 Million in the corresponding quarter of the previous year, due to the following:  1) Revenue increased by 5.7% mainly driven by the growth in the Pharma segment and the increased number of pilgrims to the Haram Mosques in Makkah & Madinah.  2) Gross Profit increased by 6.2% which is closely in line with revenue growth.  3) Operating Expenses increased by 10%. This is in line with the company's planned phasing pattern for operating expenses during the year to support the business growth.

## عام - Public





	As a result, net profit margin reached the level of 11.8% of the revenue which is closely in line with the net profit margin level of 12.1% for the same quarter of last year.
The reason of the increase (decrease) in the net profit during the current quarter compared to the previous quarter of the current year is	Net Profit decreased by -5.5% in the current quarter compared to the previous quarter due to seasonality and the occurrence of Ramadan and Hajj in the previous quarter.
The reason of the increase	Net Profit increased by 13.5% in the current period compared to the same period of last year, reaching SAR 759.8 Million, with an increase of SAR 90.5 Million compared to SAR 669.3 Million in the corresponding period of the previous year, due to the following:  1) Revenue increased by 6.3%, mainly driven by the growth within the Pharma segment and the increased number of pilgrims to the Haram Mosques in Makkah & Madinah.  2) Gross Profit increased by 7.7% as a result of sales growth and positive product mix, resulting in a gross margin improvement of 0.5% to
(decrease) in the net profit during the current period compared to the same period of the last year is	reach 41.5% of revenue in the current period compared to 41.0% in the same period of last year.  3) Operating Expenses increased by 7.6% which is in line with the company's planned phasing pattern during the year to support the business growth. The net balance of operating expenses and other operating revenue increased by 5.9% in the current period compared to the same period of last year, which is closely in line with revenue growth.  4) Net Profit increased by 13.5% driven by the growth in revenue and gross profit. The profit margin improved by 0.7% reaching 11.7% of





	revenue in the current period compared to 11.0% in the same period of last year, mainly driven by the improvement in gross margin as a result of product mix.
Statement of the type of external auditor's report	Unmodified conclusion
Reclassification of Comparison Items	Certain comparative information has been reclassified to align with current presentation for the period ended 30 September 2022.
Additional Information	There is a favorable increase in Other Comprehensive Income due to the global increase in interest rates, impacting the actuarial estimate for end-of-service indemnity.